Advancing
a New Front
in the War against Cancer

Provectus Biopharmaceuticals is
developing advanced therapies designed
to target and destroy the deadliest cancers
- melanoma, liver and breast - while
minimizing side effects


PV-10

An Investigational Drug for Cancer

PH-10

An Investigational Drug for Psoriasis and Atopic Dermatitis

IN THE MEDIA

January 22, 2015

Video: Plans for a Phase 3 Study of PV-10 in Melanoma

In a video appearing on P&T Community, Dr. Robert Andtbacka of the University of Utah discusses plans for a phase 3 trial involving PV-10 in patients with stage 3b and 3c melanoma who have failed or were not candidates for immunotherapy and patients who are BRAF-negative and who currently don’t have good treatment options.

January 20, 2015

The WallStreet Transcript Interviews Peter Culpepper, CFO, COO

Peter Culpepper, CFO and COO of Provectus, was recently interviewed by The WallStreet Transcript. In the interview, Mr. Culpepper discusses clinical development status, including a Phase 3 trial of PV-10 for melanoma and Phase 1b/2 trials of PV-10 for liver cancer and PV-10 combined with immune checkpoint blockade agents for melanoma. Mr. Culpepper also answers questions of clinical study time frames, funding, and potential partners.

January 12, 2015

India West Announces AAPI Global Clinical Trials Network

India West reports on the launch of the American Association of Physicians of Indian Origin's launch of the Global Clinical Trials Network. Provectus has committed to being the inaugural member of the Global Clinical Trial Network.

January 9, 2015

In-Pharma Technologist Reports Addition of Pfizer Director to Provectus' Strategic Advisory Board

In-Pharma Technologist reports that Deanna Angello, a Director of Commercial Strategy and New Business Planning within the Global Established Pharma business at Pfizer has joined Provectus' Strategic Advisory Board.

January 8, 2015

WallStreet Scope Reports on Recent Provectus Performance

The Mid-Day Changers section of WallStreet Scope for January 8, 2015 reports Provectus as a stock to watch.

January 8, 2015

Property Mentor Group Announces Provectus' Participation at the Annual AAPI Conference

Property Mentor Group, in the Top News section for January 8, 2015, reports on Provectus' participation at the Annual American Association of Physicians of Indian Origin Conference in Orlando.

January 8, 2015

Global clinical trials network launched during AAPI summit

An article appearing in the India Post announces the launch of the AAPI – Global Clinical Trials Network, a new initiative of American Association of Physicians of Indian Origin.

January 7, 2015

Provectus to Be Inaugural Member of the AAPI Global Clinical Trial Network

An article titled "AAPI - Global Clinical Trials Network launched during Global Healthcare Summit 2015 in Mumbai" appearing on NRI News announces the launch of the Global Clinical Trials Network, a new initiative of the American Association of Physicians of Indian Origin (AAPI). The new initiative was launched on January 4th, 2015 during the Global Health Care Summit in Mumbai in India. Provectus has committed to be the inaugural member of the Global Clinical Trial network. AAPI is looking forward to creating a large network of Pharmaceutical companies to make this initiative a great success.

January 6, 2015

Provectus Biopharmaceuticals to Meet with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Study

An article appearing on Dermwire covers news of Provectus' upcoming meeting with the US FDA to review certain operational aspects of the protocol for a planned phase 3 clinical trial of intralesional PV-10 as a treatment for melanoma. No date for this meeting has been agreed upon as yet.

December 30, 2014

Promising Strategy for Advanced Melanoma: Intralesional Therapies Plus Systemic Immunotherapies

In an article appearing in Cancer Watch, cancer researchers discuss the promising strategy of combining intralesional drugs such as PV-10, that stimulate an immune response by killing tumor cells in a manner whereby intact antigens are expressed, with drugs such as ipilimumab and pembrolizumab that act as immune checkpoint inhibitors.

December 19, 2014

Decision-Plus Interviews Provectus CFO and COO Peter Culpepper

In a video interview appearing on decisionplus.com, Peter Culpepper, CFO and COO of Provectus Biopharmaceuticals, discusses the current status of PV-10 development, regulatory events, compassionate care, and global market strategy.

December 5, 2014

Oncologists examine efficacy of rose bengal against cancer

A News Medical article discusses PV-10 clinical studies, as well as recent murine melanoma studies combining PV-10 and co-inhibitory blockade, and the recent surge in attention being given to combination therapies by both big pharma and the media.

December 5, 2014

Study Finds Combined PV-10 And Immune Checkpoint Inhibitors Efficient In Melanoma Treatment

An article appearing on Melanoma News Today reports that during the 29th annual meeting of the Society for Immunotherapy of Cancer, Dr. Shari Pilon-Thomas of the Moffitt Cancer Center, presented a study titled "Efficacy of Intralesional Injection with PV-10 in Combination with Co-Inhibitory Blockade in a Murine Model of Melanoma" revealing new results that encourage the combination of PV-10 and co-inhibitory blockade drugs for the treatment of melanoma.

December 4, 2014

Rose Bengal and Co-Inhibitory Blockade Improve Anti-Tumor Immunity, Melanoma Regression

An article appearing on Practical Dermatology's dermwire reports on data presented at the 29th annual meeting of the Society for Immunotherapy of Cancer by a team from Moffitt Cancer showing that IL PV-10 and co-inhibitory blockade could improve anti-tumor immunity and regression of melanoma in mice.

December 2, 2014

PV-10 Data Published; Phase 3 Protocol Published

An article appearing on Practical Dermatology's dermwire reports that Phase 2 PV-10 data were recently published in Annals of Surgical Oncology and that the protocol for a Phase 3 Study of PV-10 as a treatment for melanoma was published at clinicaltrials.gov.

November 20, 2014

PV-10 and checkpoint inhibitor enhance melanoma regression

An article appearing on Pharmiweb reports that data from a murine study combining PV-10 with checkpoint inhibitors (anti-CTLA, and second generation immune check point inhibitors anti-PD-1 and anti-PD-L1) show that mice injected with PV-10 and anti-PD-L1 had significant delays in tumour growth compared with mice injected with PBS + NrlgG; PBS + anti-PD-L1; or PV-10 + NrlgG. Furthermore T cells isolated from spleens of mice injected with both PV-10 and anti-PD-L1 produced significantly more interferon gamma (a surrogate for T cell reactivity) compared to the other three groups.

November 19, 2014

Combination of PV-10 and checkpoint inhibitor boosts melanoma tumour regression

An article appearing on ecancer reports on an investigation of PV-10 in combination with anti-CTLA, and the second generation immune check point inhibitors anti-PD-1 and anti-PD-L1. Data from the murine study was recently presented at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting by Moffitt Cancer Center researchers.

November 18, 2014

Melanoma shows improved regression with combination of PV-10 and checkpoint inhibitor

An article appearing on Medical News Today reports on data presented at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting showing that combination therapy of intralesional (IL) PV-10 and anti-PD-L1 antibodies enhanced regression of "bystander" (uninjected lesions) in comparison to either treatment used alone.

November 17, 2014

Provectus Biopharmaceuticals Presents PV-10 Data

An article appearing in Pharmacy Choice reports on data presented at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting supporting combination therapy with IL PV-10 and co-inhibitory blockade.

November 17, 2014

It may just be do or dye time for cancer biotechs

An article appearing in The Australian reports on investigation drug PV-10 and its promising clinical results.

more...

PRESS RELEASES

January 26, 2015

Provectus Biopharmaceuticals' Novel Synthesis Patent Application Allowed by Chinese Patent Office

Provectus announced today that it has received notification of allowance from the Chinese Patent Office for its patent application protecting the synthetic process used to produce the small molecule Rose Bengal, the active pharmaceutical ingredient (API) in PV-10, the Company's lead oncology drug candidate.

December 23, 2014

Provectus Biopharmaceuticals' Protocol for Phase 2 Study of Mechanism of Action of PH-10 on Immunologic Markers of Psoriasis Now Available Online

Provectus announced today that the protocol for its phase 2 study of the mechanism of action of PH-10 in psoriasis is now available on ClinicalTrials.gov, Identifier NCT02322086:

December 22, 2014

Provectus Biopharmaceuticals to Meet with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Study with Aim to Maximize Speed of Enrollment

Provectus announced today that it will be meeting with the U.S. Food and Drug Administration (the "FDA") to review certain operational aspects of the protocol for its planned phase 3 clinical trial of intralesional PV-10, its novel investigational drug for cancer, as a treatment for melanoma. No date for this meeting has been agreed upon as yet.

December 17, 2014

Provectus Biopharmaceuticals To Sponsor American Association of Physicians of Indian Origin

Provectus announced today that it has agreed to sponsor the activities of the American Association of Physicians of Indian Origin (AAPI). In addition, Provectus will participate at AAPI's 2015 Global Healthcare Summit in Mumbai, India, running from January 2-4, 2015, as well as at the Annual AAPI Conference in Orlando, Florida, running from June 17-21, 2015.

November 14, 2014

Provectus Biopharmaceuticals Extends Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-THINK Pharmaceutical Co., Ltd

Provectus announced today that it has agreed to extend the term of its existing Memorandum of Understanding (MOU) with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI"), the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK"), the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group to May 16, 2015. The MOU remains in effect and unchanged other than this extension of the term.

November 13, 2014

Provectus Biopharmaceuticals' Protocol for Phase 3 Study Of PV-10 As Treatment for Melanoma Now Available Online

Provectus announced today that the protocol for its phase 3 study of PV-10 as a treatment for melanoma is now available on: http://clinicaltrials.gov/ct2/show/study/NCT02288897?term=provectus&rank=6.

November 10, 2014

Provectus Biopharmaceuticals PV-10 Data Presented at SITC 29TH Annual Meeting

Provectus announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of cancer was featured in a poster presentation at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting on Saturday, November 8, 2014.

November 6, 2014

Provectus Biopharmaceuticals, Inc. Reports Third Quarter Results

Provectus today announced financial results for the third quarter of 2014.

November 6, 2014

Provectus Biopharmaceuticals Submits PV-10 Phase 3 Melanoma Protocol to FDA

Provectus announced today that it has submitted its phase 3 protocol for evaluation of PV-10 for treatment of locally advanced cutaneous melanoma to the FDA. The FDA is expected to review the submission and comment on the proposed study population, clinical endpoints, and statistical analyses within 30 to 45 days. Provectus believes details of the protocol will be available publicly on www.clinicaltrials.gov within the next few days.

November 6, 2014

Provectus Biopharmaceuticals Announces Abstract Available on Intralesional PV-10 and Co-inhibitory Blockade Data for SITC 29th Annual Meeting

Provectus announced today that the abstract titled "Efficacy of Intralesional Injection with PV-10 in Combination with Co-Inhibitory Blockade in a Murine Model of Melanoma," to be presented at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting is now available at http://www.immunotherapyofcancer.org/content/2/S3/P120.

November 6, 2014

Provectus Biopharmaceuticals, Inc. to Hold Quarterly Conference Call Today at 4 PM Eastern Standard Time

Provectus will host its quarterly conference call today, Thursday, November 6, 2014 at 4:00 PM EST.

October 31, 2014

Provectus Biopharmaceuticals, Inc. to Hold Quarterly Conference Call on Thursday, November 6, 2014

Provectus will host a quarterly conference call to update the market in general and shareholders in particular about developments at the Company. The call is scheduled for Thursday, November 6, 2014 at 4:00 PM EST.

October 28, 2014

Provectus' Intralesional PV-10 Clinical Data Published in the Annals of Surgical Oncology

Provectus announced today that data on its investigational new drug PV-10, obtained in clinical trial PV-10-MM-02 ( ClinicalTrials.gov Identifier NCT00521053), has been published by the Annals of Surgical Oncology (ASO).

October 16, 2014

Provectus' Intralesional PV-10 Clinical Data to Be Presented to the 2014 International Congress of the Society for Melanoma Research

Provectus announced today that Sanjiv S. Agarwala, MD, of St. Luke's University Hospital and Professor of Medicine at Temple University will present data on its investigational new drug PV-10 for the treatment of melanoma at the 11th International Congress of the Society for Melanoma Research in Zurich, Switzerland.

October 15, 2014

Provectus' Intralesional PV-10 and Co-Inhibitory Blockade Data to Be Presented at SITC 29th Annual Meeting

Provectus announced today that Shari Pilon-Thomas, Ph.D. from the Moffitt Cancer Center will present the abstract titled "Efficacy of Intralesional Injection with PV-10 in Combination with Co-Inhibitory Blockade in a Murine Model of Melanoma," at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting in two time slots on Saturday, November 8: 12:30 pm - 2:00 pm and 6:00 pm - 7:30 pm.

October 14, 2014

INC Research Signs Agreement to Perform FDA Due Diligence Audit of Regulatory Documents for Provectus Biopharmaceuticals

Provectus announced today that it has retained INC Research, a leading, global Phase I to IV contract research organization, to conduct an FDA due diligence audit of its regulatory documents for PH-10 and PV-10.

October 8, 2014

Provectus' Intralesional PV-10 Clinical Data to Be Presented to the Eurasian Federation of Oncology

Provectus announced today that Dr. Sanjiv Agarwala of St. Luke's Cancer Center will present data on its investigational new drug PV-10 for the treatment of melanoma at the III Eurasian Melanoma and Skin Cancers Forum, in Suzdal, Russia.

October 7, 2014

Provectus' Intralesional PV-10 to Be Presented at the 2014 Beijing International Melanoma Congress

Provectus announced today that clinical data on its investigative new drug PV-10 for the treatment of melanoma will be presented at the 2014 Beijing International Melanoma Congress. The presentation by Dr. Sanjiv Agarwala of the St. Luke's Cancer Center is titled "Current Perspectives on Intralesional Therapies." It is scheduled for 5:30 pm local time, on Saturday, October 18, 2014.

September 29, 2014

Provectus Biopharmaceuticals Data Presented At ESMO 2014 Congress Show Ablative, Bystander Effects Of PV-10

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of locally advanced cutaneous melanoma was featured in a poster presentation on Sunday, September 28, 2014 during the European Society For Medical Oncology 2014 Congress in Madrid, Spain. The presentation showed that PV-10 elicits a high rate of response in injected tumors through its ablative effect, and additionally, that the durability of response as well as the bystander response in uninjected tumors implicate an additional immunologic mechanism secondary to ablation.

September 24, 2014

Provectus Biopharmaceuticals' PV-10 Clinical Data on Melanoma Now Available for European Society for Medical Oncology 2014 Congress

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (www.pvct.com), announced today that the abstract entitled, "Subgroup efficacy in patients receiving intralesional rose bengal to all existing melanoma in phase II study PV-10-MM-02," to be presented at the European Society for Medical Oncology 2014 Congress, is now available at
https://www.webges.com/cslide/library/esmo/browse/search/8ct#9faD03sJ.

more...